CD274 and neoplasm: PD-L1 tumor proportion score (TPS) was available for 84% (N = 274) of the cohort and was < 1% among 36% of patients (N = 98), 1–49% among 27% (N = 75), 50–89% among 22% (N = 61), and ≥90% among 15% (N = 40).